Diabetologia(2012)55:36–45
DOI10.1007/s00125-011-2357-4
ARTICLE
Design, history and results of the Thiazolidinedione
Intervention with vitamin D Evaluation (TIDE)
randomised controlled trial
The TIDE Trial Investigators
Received:5September2011/Accepted:6October2011/Publishedonline:29October2011
#Springer-Verlag2011
Abstract 6.5–9.5% (48–80 mmol/mol) when using two or fewer
Aims/objective Conflicting data regarding cardiovascular glucose-lowering drugs were randomised by a central
effects of thiazolidinediones (TZDs) and extra-skeletal computer system to placebo (n=541), rosiglitazone 4–
effects of vitamin D supported the need for a definitive 8 mg/day (n=399) or pioglitazone 30–45 mg/day (n=392);
trial. The Thiazolidinedione Intervention with vitamin D 1,221 participants were randomised to placebo (n=614) or
Evaluation(TIDE)trialaimedtoassesstheeffectsofTZDs vitamin D 1,000 IU/day (n=607). Participants and all study
(rosiglitazone and pioglitazone) on cardiovascular out- personnel were blind to treatment allocation. The
comes and the effects of vitamin D (cholecalciferol) on primary outcome for the TZD arm was the composite
cancers and mortality. of myocardial infarction, stroke or cardiovascular death,
Methods A large multicentre 3×2 factorial double-blind and for the vitamin D arm it was cancer or all-cause
placebo-controlledrandomisedtrialrecruitedfromoutpatient death. All randomised participants were included in the
primarycareandspecialtyclinicsin33countries.FromJune primary analysis.
2009toJuly2010,1,332peoplewithtype2diabetesandother Results From the study design, 16,000 people were to be
cardiovascularriskfactorsaged≥50yearswhoseHbA was followed for approximately 5.5 years. However, the trial
1c
was stopped prematurely because of regulatory concerns
after a mean of 162 days without consideration of the
accrued data. In the TZD arm, the cardiovascular outcome
TheTIDETrialInvestigatorsWritingCommitteeZ.Punthakeeand
J.Bosch(PopulationHealthResearchInstituteMcMasterUniversity, occurred in five participants (0.9%) in the placebo groups
Hamilton,ON,Canada);G.Dagenais(InstitutUniversitairedeCardiologie and three participants (0.4%) in the TZD groups (two
etdePneumologiedeQuébecUniversitéLaval,Québec,QC,Canada);
allocated to pioglitazone, one to rosiglitazone). In the
R.Diaz(InstitutoCardiovasculardeRosario,Rosario,Argentina);R.Holman
vitamin D arm, the primary outcome occurred in three
(OxfordCentreforDiabetesOxford,UK);J.L.Probstfield(Universityof
WashingtonSeattle,WA,USA);A.Ramachandran(IndiaDiabetes participants (0.5%) in the placebo group and in two
ResearchFoundationChennai,India);M.C.Riddle(OregonHealth& participants (0.3%) receiving vitamin D. Adverse events
ScienceUniversityPortland,OR,USA);L.E.Rydén(KarolinskaInstitutet
were comparable in all groups.
Stockholm,Sweden);B.Zinman(UniversityofToronto,Toronto,ON,
Conclusions/interpretation Uncertainty persists regarding
Canada);R.Afzal,S.YusufandH.C.Gerstein(PopulationHealth
ResearchInstitute,McMasterUniversity,Hamilton,ON,Canada). the clinically relevant risks and benefits of TZDs and
vitamin D because of the early cancellation of this
Electronicsupplementarymaterial Theonlineversionofthisarticle
comprehensive trial.
(doi:10.1007/s00125-011-2357-4)containspeer-reviewedbut
uneditedsupplementarymaterial,includingalistoftheTIDETrial
Investigators,whichisavailabletoauthorisedusers. Trial registration: ClinicalTrials.gov NCT00879970
TheTIDETrialInvestigators(*) Funding: The study was funded by GlaxoSmithKline.
c/oZ.Punthakee,
PopulationHealthResearchInstitute,McMasterUniversity, Keywords Cardiovascular disease.Pioglitazone.Placebo-
237BartonStE.,
controlled randomised trial.Rosiglitazone.Type 2
Hamilton,ON,CanadaL8L2X2
e-mail:zubin.punthakee@mcmaster.ca diabetes.Vitamin D
Diabetologia(2012)55:36–45 37
Abbreviations 5.7 years [35]. This, and evidence of a neutral effect of
ALT Alanine aminotransferase 400 IU/day on cancers and cardiovascular outcomes [36–
eGFR Estimated GFR 38] and a beneficial effect of 1,100 IU/day on cancer risk
FDA Food and Drug Administration [39],suggestthathigherdosesofvitaminDmightimprove
TIDE Thiazolidinedione Intervention with vitamin D health outcomes in people with diabetes.
Evaluation trial The Thiazolidinedione Intervention with vitamin D
TZD Thiazolidinedione Evaluation(TIDE)trialwasdesignedtoexplicitlydetermine
whether the TZDs and/or vitamin D can safely reduce
clinically important outcomes. It was designed by an
Background international scientific committee of ten experts in clinical
trials, diabetes and cardiovascular disease plus a representa-
The thiazolidinediones (TZDs) rosiglitazone and pioglita- tive from the sponsor (GlaxoSmithKline—the manufacturer
zone lower glucose levels without causing hypoglycaemia of rosiglitazone), with input from representatives of the US
[1].Theyalsoreducemanyothercardiovascularriskfactors FoodandDrugAdministration(FDA)whoapprovedthefinal
including: incident diabetes [2, 3]; insulin resistance [4, 5]; design.GlobalimplementationofTIDEwasledbythisgroup
blood pressure [6]; albuminuria [7]; renal disease [8, 9]; and35otherexperts.Itwassubsequentlyapprovedbyatotal
inflammatory markers [10]; revascularisation after percuta- of33regulatoryagenciesand525researchethicscommittees
neous coronary intervention [11]; and carotid [3, 12–14] in33countries.Itsprogressandsafetyweremonitoredbyan
and coronary atherosclerosis [15, 16]. These observations independent data-monitoring committee of five international
and analyses of data from administrative databases in 2005 experts. Notwithstanding these approvals and safeguards,
show that people prescribed TZDs may have fewer therewasongoingpubliccontroversyregardingthesafetyof
cardiovascular events or deaths than people prescribed rosiglitazone [40], prompted by a US Senate Committee
other agents [17, 18] and suggest that TZDs may improve report [41], and an advisory board was convened by the
cardiovascular outcomes. This hypothesis gained support FDA [42, 43]. On 21 July 2010, the FDA suspended
from trials showing that: (1) insulin-sensitising therapies recruitment into the trial, and on 23 September 2010 it
(comprising mainly rosiglitazone plus metformin) had requiredwithdrawaloftreatmentforallparticipantsenrolled
effects on mortality and cardiovascular events comparable inthe TIDEtrial.Thispaper reports the course ofthe TIDE
with those of insulin-providing therapies in people with trial and its accrued outcomes by treatment group in the
diabetes and proven coronary artery disease [19]; (2) the context of these decisions.
cardiovascular effects of rosiglitazone in combination with
either metformin or a sulfonylurea were similar to those of
metformin plus a sulfonylurea [20]; and (3) pioglitazone Methods
non-significantly reduced cardiovascular events compared
with a placebo [21]. However, the limitations of the TIDE was a 3×2 factorial double-blind randomised
methods of the latter two trials [22–24], the higher risk of placebo-controlled trial. Volunteers were enrolled from
heartfailurewithTZDs[25],analysesofotheradministrative primary care, diabetes and cardiology clinics if they had
databases, and inconclusive meta-analyses of mainly small type 2 diabetes and an HbA level ranging from 6.5% to
1c
trials comprising few events [26–30] raised uncertainty 9.5%(48to80mmol/mol),weredrug-naiveortakingupto
regarding the cardiovascular safety of rosiglitazone and the two non-insulin glucose-lowering medications, and were at
effects of the TZDs as a class. Collectively, these observa- risk of cardiovascular disease on the basis of: (1) age at
tions highlighted the need for a definitive trial testing the least 50 years with a prior cardiovascular event; (2) age at
hypothesisthatTZDsmayimprovecardiovascularoutcomes least55yearswithdocumentedarterialstenosis,albuminuria,
in patients with diabetes and other cardiovascular risk ankle brachial index <0.9 or left ventricular hypertrophy; or
factors. (3)ageatleast60yearswithatleasttworiskfactors(tobacco
Emerging evidence suggests that type 2 diabetes is use, high LDL-cholesterol, low HDL-cholesterol or high
associatedwithlowlevelsofvitaminD[31],andagrowing triacylglycerols, hypertension or obesity). Key exclusion
bodyofevidencelinksvitaminDdeficiencytomanyofthe criteria were a cardiovascular event within 30 days before
chronic diseases that occur in people with diabetes, randomisation, history of pulmonary oedema, symptomatic
including cancer [32] and cardiovascular disease [33, 34]. heart failure (New York Heart Association class II–IV),
The possibility that vitamin Dsupplementationmay reduce knownleftventricularejectionfractionbelow40%oruseof
these risks was suggested by a recent meta-analysis of 18 aloopdiuretic,cancerdiagnosedintheprior3yearsoractive
randomisedcontrolledtrialsinwhichameanof528IU/day treatmentforcancer(otherthannon-melanomaskincanceror
of vitaminD reduced total mortality by 7% over amean of cervicalcarcinoma insitu),fractureinthe prior year, known
38 Diabetologia(2012)55:36–45
osteomalacia, or hypercalcaemia. The protocol and consent Statistical analysis Sample size calculations showed that
forms were approved by ethics committees at all recruiting 16,000 participants would provide approximately 90%
centres, and all participants provided written informed power to detect a 20% or greater reduction in the primary
consent. outcome of TZDs vs placebo, assuming an annual event
After 3 weeks of active rosiglitazone and vitamin D rate of 2%, 2 years of recruitment, 5.5 years of follow-up,
(cholecalciferol) run-in, participants were randomised by a and a two-sided α between 0.025 and 0.05. This sample
central phone-in computer system to placebo, pioglitazone size would include 10,888 people randomised to either
30 mg daily or rosiglitazone 4 mg daily at a 4:3:3 ratio. rosiglitazone or placebo and would exclude a 30% excess
Doses were to be increased to pioglitazone 45 mg daily or ofeventswithrosiglitazonecomparedwithplacebousinga
rosiglitazone8mgdailyby12months.Independentoftheir one-sided α level of 0.0125 during a safety analysis after
TZD allocation, participants were also randomised to 4.5years.Thestudywouldalsohave90%powertodetecta
placebo or vitamin D, 1,000 IU daily, in a 1:1 ratio. Due 26% reduction in mortality or serious cancer with vitamin
to manufacturing delays, the vitamin D study drug was not Dover5.5yearsand18%over10yearsassuminganevent
available at the start of the trial. Thus approximately 40% rate of this composite outcome of 1% per year.
of the vitamin D participants were randomised to the Data were collected, stored and analysed centrally at the
vitamin D arm after randomisation to the TZD arm. The Population Health Research Institute project office inde-
management of glucose levels and all other conditions was pendent of the sponsor. Statistical analyses were conducted
at the discretion of the local physician as informed by using SAS version 9.1 software (SAS Institute). All group
clinicalpracticeguidelinesandtherelevantevidence;open- comparisons were done according to the intention-to-treat
labelTZDswerenotpermitted.Studyvisitswereconducted approach. Kaplan–Meier and Cox regression analyses were
2 and 6 months after randomisation and every 6 months planned. However, following early termination of the trial
thereafter. and prior to unblinding, the scientific committee deter-
The primary outcome measure for the TZD arm was the minedthatsuchanalyseswouldbeinappropriatebecauseof
first occurrence of the composite of myocardial infarction, the small numbers of outcomes. Characteristics of partic-
strokeorcardiovasculardeath,andforthevitaminDarmit ipants at baseline and at the end of the study are tabulated
was all-cause death or cancers requiring hospitalisation, as means±SD or number (percentage) and end-of-study
chemotherapy or surgery. Other outcomes included a comparisons were made by Student’s t tests or χ2 tests.
composite microvascular outcome (the first occurrence of Incidence rates of primary outcomes, secondary outcomes
retinopathy requiring laser therapy or vitrectomy, or a 30% and any safety events were calculated by dividing the
decline in estimated GFR [eGFR], or need for renal numberofindividualsexperiencinganeventbytheperson-
replacement therapy) for the TZD arm, and hospitalisation years of follow-up (from randomisation to the time of an
for heart failure, pneumonia or shortness of breath, event or censoring).
hospitalisation for any reason, revascularisation and frac-
tures for both study arms. All outcomes except decline in
eGFR and hospitalisation for any reason were adjudicated
according to prespecified criteria, without knowledge of Results
study-group allocation.
Serum calcium was measured at baseline, at 2 months The first participant was randomised in June 2009. By the
and at the annual and end-of-study visits. Fasting lipids, end of January 2010 a total of 143 randomised individuals,
serum creatinine and alanine aminotransferase (ALT) were 157centres,and18countrieswereparticipating,andbythe
measured at baseline and end-of-study visits. Fasting end of February when the US Senate report was released,
plasma glucose and HbA were measured at baseline, this had risen rapidly to 204 participants, 202 centres,
1c
after 1 year and at the end-of-study visits. All blood tests and 20 countries. By the time recruitment was sus-
were assayed locally. To facilitate cross-site comparisons, pended at the end of July 2010, 455 centres located in
if the upper limit of normal for the locally measured 33 countries were eligible to recruit participants.
HbA result was not 6% (42 mmol/mol), the measured However, despite the addition of 253 centres with ethics
1c
value was divided by the upper limit of normal and approvals after February, the proportion of centres that
multiplied by 6%. HbA values measured using the were screening participants subsequently decreased
1c
International Federation of Clinical Chemistry or related (Fig. 1).Thus,atotalof1332participantswereultimately
methods were converted to the Diabetes Control and randomisedinonly175ofthe455centrestotheTZDarm
Complications Trial-National Glycohaemoglobin Stand- (541 to placebo, 392 to pioglitazone, and 399 to
ardisationProgram (DCCT-NGSP) values using published rosiglitazone) and 1,221 to the vitamin D arm (614 to
regression equations [44]. placebo and 607 to vitamin D). Figure 1 illustrates the
Baseline characteristics of participants were similar
100
across allocated groups (Table 1). The mean age of
80 participants was 66.4±6.6 years, 41% were women and
35%hadpriorcardiovasculardisease.Themeandurationof
60 diabetes was 8.8±6.9 years and the mean HbA was 7.4±
1c
0.9% (57±10 mmol/mol). Mean duration of follow-up was
40
162 days (i.e. 590 person-years) for the TZD arm and
20 130 days (i.e. 546 person-years) for the vitamin D arm. Of
the 1325 surviving participants contacted before it was
0
Jun−Dec J F M A M J J announced that the trial would be stopped, 90% (n=1,187)
and91%(n=1,018)wereatleast80%adherenttotheTZD
and vitamin D study drugs, respectively (91% to
placebo [n=487], 87% to pioglitazone [n=341], and
300 91% to rosiglitazone [n=359]; 92% to placebo [n=519]
and 91% to vitamin D [n=499]). A mean of 2.2% of
200 participants stopped the study drug per month before the
Senate report was publicised, whereas a mean of 2.5% of
100
participants stopped the study drug per month in the
3 months prior to the announcement of trial termination.
0
Between that announcement and the end-of-study visit,
500 participants were stopping the study drug at a high rate of
18% per month; thus by the end-of-study visit, 39% of
400
participants had stopped the TZDstudy drug (n=516) and
300
34% had stopped the vitamin D study drug (n=417). The
200
most common reasons for stopping the TZD study drug
100 either temporarily or permanently during the trial were
0 hearing that the trial was terminated (56%, n=288),
adverse events (22%, n=115) and fear of adverse events
(12%, n=62). The most common reasons for stopping the
vitamin D study drug were hearing the trial was
terminated (69%, n=288), adverse events (13%, n=56)
and fear of adverse events (5%, n=21).
Adjudicated outcomes are presented in Table 2 and
the outcomes as reported (i.e. prior to adjudication) are
shown in Electronic supplementary material (ESM)
2009 2010 Table 1. The primary composite cardiovascular outcome
occurred in five (0.9%) participants in the placebo group
and three (0.4%) participants in the TZD group (two
allocated to pioglitazone and one allocated to rosiglita-
zone). The primary outcome for the vitamin D study (all-
cause mortality or serious cancers) occurred in three
(0.5%) placebo group participants and two (0.3%)
vitamin D group participants.
Physical measurements, metabolic variables and use of
concomitantglucose-loweringmedicationsattheendofthe
numbers of participating countries, participating centres trial are shown in Table 3. Compared with placebo,
and randomised participants by month. During the trial, participants randomised to a TZD (pioglitazone and
six participants died, two participants were lost-to-follow- rosiglitazone groups combined) achieved lower HbA
1c
up, and ten participants withdrew consent. All other (6.9% vs 7.3% [52 vs 56 mmol/mol], p<0.001), fasting
participants were followed until the end of the study, and plasma glucose (7.2 vs 8.0 mmol/l, p<0.001) and ALT (25
vitalstatuswasknownfor1,320(99.1%)participants.The vs 27 U/l, p=0.006), and increased their weight (88.0 vs
disposition of participants by treatment group is shown in 85.2kg,p=0.008)andBMI(31.5vs30.4kg/m2,p=0.001).
Fig. 2a, b. Compared with pioglitazone, the rosiglitazone group had
lla
fo
tnec
reP
stnapicitraP
evitalumuC
evitalumuC
gnineercs
sertnec
)n(
desimodnar
)n(
sertnec
)n(
seirtnuoc
Diabetologia(2012)55:36–45 39
a
b
c
d
40
30
20
10
0
J J A S O N D J F M A M J J
Fig. 1 Recruitment potential and activity are shown by calendar
month (denoted by the first letter of the month on the x-axis). The
panels illustrate: (a) the percentage of centres recruiting; (b) the
numbers of participants randomised each month; (c) cumulative
numbers of centres with ethics approval eligible to recruit; and (d)
cumulativenumbersofcountrieswithregulatoryapprovalforthetrial.
ThearrowindicatesthereleasedateoftheUSSenateReport
40 Diabetologia(2012)55:36–45
a b
2,434 Screened 2,434 Screened
1,102 Excluded: 1,213 Excluded:
14 withdrew consent 14 withdrew consent
350 HbA1c out of range 49 hypercalcaemic
72 failed run-in TZD 1,045 otherwise ineligible
674 otherwise ineligible 111 study drug unavailable
1,332 Randomised to TZD arm 1,221 Randomised to vitamin D arm
541 Placebo 392 Pioglitazone 399 Rosiglitazone 614 Placebo 607 Vitamin D
4 Died 1 Died 1 Died 2 Died 0 Died
1 Lost 0 Lost 1 Lost 0 Lost 1 Lost
3 Withdrew 3 Withdrew 4 Withdrew 2 Withdrew 6 Withdrew
214 Stopped drug 150 Stopped drug 152 Stopped drug 205 Stopped drug 212 Stopped drug
541 Analysed by 392 Analysed by 399 Analysed by 614 Analysed by 607 Analysed by
intention to treat intention to treat intention to treat intention to treat intention to treat
Fig.2 Trialprofilesofparticipantsbasedonallocationto(a)theTZD mised to the TZD arm were not randomised to the vitamin D arm
arm, and (b) the vitamin D arm. Multiple reasons are possible for because the vitamin D study drug was not available at the time of
excluded or non-completed individuals. The 111 participants rando- studytermination
slightlyhigherHbA (7.0%vs6.8%[53vs51mmol/mol], Discussion
1c
p=0.024), and also higher triacylglycerols (2.10 vs
1.67 mmol/l, p<0.001), and lower HDL-cholesterol (1.19 ThepurposeoftheTIDEtrialwastoelucidatetheeffectof
vs1.27mmol/l,p=0.003)attheendofthetrial.Theuseof TZDs on cardiovascular events while also elucidating the
statins, ACE inhibitors or angiotensin receptor blockers, effectofvitaminDoncanceranddeathinpeoplewithtype
anti-plateletagents,diureticsandnitratesweresimilaratthe 2 diabetes and other cardiovascular risk factors. TIDE was
end of the trial (data not shown). Vitamin D did not affect designed to recruit 16,000 participants over 2 years and
physical measurements, biochemistry (including serum wouldhaveincluded816sitesin39countriesonceallsites
calcium) or concomitant medication use. were activated. Based on the observed recruitment rates in
Severe hypoglycaemia (i.e. hypoglycaemia requiring early 2010, plans to add more sites, and ongoing support
assistance from another person, with either a documented for continuation of the trial by the unblinded Independent
plasma glucose≤2.0 mmol/l or prompt recovery after oral Data Monitoring Committee, it is likely that recruitment
carbohydrate, intravenous glucose, or glucagon administra- would have rapidly increased until its completion in mid
tion) occurred in none of the participants in the placebo 2011.However,theheatedpoliticaldebate,globalcoverage
group,two(0.5%)inthepioglitazonegroupandone(0.3%) and public controversy surrounding both the trial and
in the rosiglitazone group. Hospital admission for conges- rosiglitazone attenuated recruitment and led to random-
tive heart failure occurred in one (0.2%) participant in the isation of only 1,332 of the planned 16,000 participants by
placebo group, two (0.5%) in the pioglitazone group and the time recruitment was stopped. Eight of these 1,332
none in the rosiglitazone group. Fractures occurred in two suffered the composite primary outcome during a mean
(0.4%) participants in the placebo group, two (0.5%) inthe follow-up period of just 0.4 years of receiving TZD study
pioglitazone group and three (0.8%) in the rosiglitazone drug—a number from which no conclusions can be drawn.
group. Severe adverse events were reported in seven The TZDs both reduced HbA and ALT levels and
1c
placebo participants, five pioglitazone participants and increased weight, whereas pioglitazone but not rosiglita-
two rosiglitazone participants, and in the vitamin D arm, zone modestly reduced triacylglycerol and raised HDL-
by two placebo participants and nine vitamin D partic- cholesterol levels compared with placebo.
ipants. Serious adverse events, tabulated in ESM Table 2, Uncertainty will persist regarding clinically relevant
included two cardiovascular, three respiratory, two gastro- risks and benefits of either rosiglitazone or pioglitazone.
intestinal, three genitourinary, one multi-organ failure, one Indeed, clinical equipoise regarding the cardiovascular
pruritic allergic and two hypoglycaemic events. Each effects of the TZDs prompted the American Heart Associ-
specific serious adverse event type occurred in only one ation and the American College of Cardiology to advocate
person, except for hypoglycaemia which was reported in jointly the conduct of definitive cardiovascular outcomes
two participants. trialssuchasTIDEasrecentlyas2010[22].Suchtrialsare
Diabetologia(2012)55:36–45 41
Table1 Participantcharacteristicsatbaseline
Characteristic TZDarm VitaminDarm
Placebo Pioglitazone Rosiglitazone Placebo VitaminD
n=541 n=392 n=399 n=614 n=607
Female 220(41) 167(43) 161(40) 254(41) 245(40)
Age(years) 66.4±6.8 66.3±6.6 66.5±6.4 66.6±6.3 66.7±6.7
Durationofdiabetes(years) 8.7±6.9 8.5±6.3 9.1±7.3 8.9±6.9 8.9±7.0
Weight(kg) 85.2±17.9 85.4±18.2 86.0±18.3 85.8±18.2 85.9±18.1
BMI(kg/m2) 30.4±5.2 30.6±5.4 30.7±5.3 30.7±5.3 30.6±5.3
Waist/hipratio 0.98±0.09 0.98±0.08 0.98±0.08 0.98±0.08 0.98±0.09
Systolicbloodpressure(mmHg) 137±18 139±17 138±17 138±18 137±17
Diastolicbloodpressure(mmHg) 80±11 80±10 81±11 80±11 80±10
Heartrate(beatsperminute) 72±11 72±11 71±11 71±11 72±11
Race/ethnicity
White 330(61) 241(62) 255(64) 379(62) 378(62)
SouthAsian 63(12) 46(12) 48(12) 64(10) 62(10)
Black 45(8.3) 35(8.9) 26(6.5) 56(9.1) 48(7.9)
LatinAmerican 33(6.1) 26(6.6) 24(6.0) 37(6.0) 46(7.6)
EastAsian 12(2.3) 6(1.5) 7(1.8) 10(1.6) 9(1.5)
Other 57(11) 38(10) 39(10) 68(11) 63(10)
Education
≤12years 309(57) 234(60) 231(58) 352(57) 351(58)
>12years 231(43) 158(40) 168(42) 262(43) 255(42)
Regularalcoholuse 173(32) 143(37) 131(33) 210(34) 214(35)
Currenttobaccouse 64(12) 46(12) 56(14) 75(12) 76(13)
BMI>30kg/m2 258(48) 187(48) 190(48) 297(48) 288(47)
Hypertension 475(88) 346(88) 353(89) 545(89) 527(87)
Dyslipidaemia 408(75) 299(76) 309(77) 467(76) 468(77)
Cardiovasculardisease 187(35) 131(33) 142(36) 209(34) 204(34)
Myocardialinfarction 74(14) 54(14) 51(13) 80(13) 78(13)
Stroke 19(3.5) 15(3.8) 15(3.8) 27(4.4) 17(2.8)
Heartfailure(NYHAIonly) 14(2.6) 11(2.8) 13(3.3) 12(2.0) 7(1.2)
Laser/vitrectomyforretinopathy 12(2.2) 9(2.3) 9(2.3) 20(3.3) 10(1.6)
Cancer 32(5.9) 23(5.9) 24(6.0) 33(5.4) 42(6.9)
Osteoporosis 15(2.8) 10(2.6) 9(2.3) 14(2.3) 18(3.0)
Fracture 75(14) 45(12) 60(15) 89(15) 85(14)
Glucose-loweringmedication 493(91) 360(92) 374(94) 574(94) 551(91)
Biguanide 442(82) 313(80) 325(82) 499(81) 488(80)
Sulfonylurea 248(46) 188(48) 209(52) 286(47) 293(48)
TZD 26(4.8) 17(4.3) 17(4.3) 29(4.7) 29(4.8)
DPP4inhibitor 15(2.8) 8(2.0) 14(3.5) 15(2.4) 19(3.1)
Other 12(2.2) 11(2.8) 7(1.8) 16(2.6) 11(1.8)
Statin 353(65) 263(67) 265(66) 413(67) 395(65)
ACEinhibitorand/orARB 401(74) 297(76) 285(71) 463(75) 441(73)
Thiazidediuretic 167(31) 115(29) 122(31) 198(32) 181(30)
Otherdiuretic 51(9.4) 34(8.7) 45(11.3) 48(7.8) 65(10.7)
Antiplateletagent 306(57) 214(55) 220(55) 329(54) 356(59)
Nitrate 33(6.1) 23(5.9) 17(4.3) 34(5.5) 30(4.9)
VitaminDsupplement 57(11) 47(12) 51(13) 71(12) 78(13)
HbA
1c
% 7.3±0.9 7.4±0.8 7.4±0.9 7.4±0.9 7.3±0.9
mmol/mol 56±10 57±9 57±10 57±10 56±9
42 Diabetologia(2012)55:36–45
Table1 (continued)
Characteristic TZDarm VitaminDarm
Placebo Pioglitazone Rosiglitazone Placebo VitaminD
n=541 n=392 n=399 n=614 n=607
Fastingplasmaglucose(mmol/l) 7.9±2.2 7.9±2.2 7.9±2.2 7.9±2.1 7.8±2.1
Serumcreatinine(μmol/l) 83±26 81±23 84±27 82±25 84±25
ALT(U/l) 28±15 28±15 28±13 28±15 27±13
Totalcholesterol(mmol/l) 4.61±1.11 4.53±1.09 4.53±1.17 4.53±1.09 4.53±1.11
Triacylglycerols(mmol/l) 1.83±1.22 1.91±1.25 1.92±1.11 1.92±1.41 1.84±0.97
HDL-cholesterol(mmol/l) 1.19±0.36 1.19±0.31 1.17±0.31 1.17±0.34 1.19±0.34
LDL-cholesterol(mmol/l) 2.62±0.98 2.56±0.91 2.54±0.96 2.54±0.91 2.56±0.96
Serumcalcium(mmol/l) 2.35±0.13 2.35±0.13 2.35±0.13 2.35±0.13 2.35±0.13
Dataarepresentedasmean±SDorn(%)
Regularalcoholuse:atleastonceperweek
Cardiovasculardisease:myocardialinfarction;stroke;stableorunstableangina;valvularheartdisease;arrhythmia;cardiacarrest;heartfailure;
coronary,carotidorperipheralrevascularisation;amputationorintermittentclaudication
ACE,angiotensin-convertingenzyme;ARB,angiotensin2receptorblocker;DPP4,dipeptidylpeptidase4;NYHA,NewYorkHeartAssociation
Table2 Clinicalevents
Event TZDarm VitaminDarm
Placebo(n=541 Pioglitazone(n=392 Rosiglitazone(n=399 Placebo(n=614 VitaminD(n=607
[237person-years]) [174person-years]) [178person-years]) [275person-years]) [271person-years])
n Ratea n Ratea n Ratea n Ratea n Ratea
Primarycardiovascularoutcome 5 2.1 2 1.1 1 0.5 3 1.3 2 0.9
Cardiovasculardeath 1 0 0 1 0
Non-fatalmyocardialinfarction 2 0 1 1 1
Non-fatalstroke 2 2 0 1 1
Anyrevascularisation 6 2.5 3 1.7 5 2.8 7 3.2 5 2.3
Hospitalisationforheartfailure 1 2 0 0 2
Hospitalisationfordyspnoea 0 1 2 0 1
Hospitalisationforpneumonia 0 1 0 0 0
Hospitalisationforanyreason 31 13.5 16 9.3 24 13.9 19 8.8 32 15.3
Deathorseriouscancer 6 2.5 3 1.7 1 0.5 3 1.3 2 0.9
Alldeath 4 1 1 2 0
Seriouscancer 2 2 0 1 2
Compositemicrovascularoutcome 21 8.8 8 4.5 9 5 18 8.2 18 8.3
Retinalphotocoagulation 1 0 0 0 0
Vitrectomy 0 0 0 0 0
Renalreplacementtherapy 0 0 0 0 0
≥30%declineineGFR 20 8 9 18 18
Severehypoglycaemia 0 2 1 0 3
Fracture 2 2 3 3 3
Numberofindividualsrandomisedisshowninthecolumnheadings,withperson-yearsinparentheses
Severehypoglycaemia:hypoglycaemiarequiringassistancefromanotherpersonandeitherdocumentedplasmaglucose≤2.0mmol/lorprompt
recoveryafteroralcarbohydrate,intravenousglucose,orglucagonadministration
aIncidenceratesareshownper100person-years
Diabetologia(2012)55:36–45 43
Table3 Physicalmeasurements,biochemistryanddiabetesmedicationuseatstudyend
Measure TZDarm VitaminDarm
Placebo Pioglitazone Rosiglitazone Placebo VitaminD
Physicalmeasurements
Weight(kg) 85.2±17.1** 88.1±18.0 87.9±18.2 86.9±18.1 86.9±17.6
BMI(kg/m2) 30.4±5.3** 31.6±6.0 31.4±5.6 31.1±5.7 30.9±5.5
Waist/hipratio 0.97±0.08 0.97±0.08 0.97±0.09 0.97±0.08 0.97±0.08
Systolicbloodpressure(mmHg) 134±17 135±17 135±17 135±17 134±16
Diastolicbloodpressure(mmHg) 78±10 78±10 78±11 78±10 78±10
Heartrate 72±12 71±10 71±12 71±11 71±11
Biochemicalmeasurements
HbA (%) 7.3±1.1*** 6.8±0.9† 7.0±0.9 7.0±1.0 7.1±1.0
1c
HbA (mmol/mol) 56±12*** 51±10† 53±10 53±11 54±11
1c
Fastingplasmaglucose(mmol/l) 8.0±2.6*** 7.2±2.2 7.2±2.3 7.5±2.3 7.5±2.4
Serumcreatinine(μmol/l) 84±30 83±25 86±26 83±24 86±31
ALT(U/l) 27±14** 24±11 25±12 25±13 25±12
Totalcholesterol(mmol/l) 4.53±1.09 4.58±1.11 4.71±1.17 4.56±1.14 4.64±1.09
Triacylglycerols(mmol/l) 1.82±1.02 1.67±0.99††† 2.10±1.30 1.83±1.08 1.88±1.12
HDL-cholesterol(mmol/l) 1.19±0.36 1.27±0.34†† 1.19±0.36 1.22±0.34 1.22±0.34
LDL-cholesterol(mmol/l) 2.56±0.93 2.62±0.96 2.64±0.98 2.56±0.93 2.64±0.96
Serumcalcium(mmol/l) 2.35±0.13 2.35±0.13 2.35±0.10 2.35±0.10 2.35±0.13
Glucose-loweringmedication
Biguanide 422(83) 287(78) 300(81) 490(83) 460(79)
Sulfonylurea 238(47) 159(43) 184(50) 266(45) 273(47)
Non-studyTZD 6(1.2) 6(1.6) 4(1.1) 5(0.8) 9(1.5)
DPP4inhibitor 19(3.7) 11(3.0) 13(3.5) 22(3.7) 19(3.3)
Insulin 3(0.6) 1(0.3) 2(0.5) 2(0.3) 4(0.7)
Other 10(2.0) 9(2.5) 6(1.6) 13(2.2) 9(1.5)
Dataarepresentedasmean±SDorn(%)
Forglucose-loweringmedicationuse,denominatorsarethe1,249TZDarmparticipantsandthe1,175vitaminDarmparticipantswhoprovided
medicationdataatthefinalvisit
**p<0.01 and ***p<0.001 for placebo vs TZDs (pioglitazone and rosiglitazone groups combined); †p<0.05, ††p<0.01 and †††p<0.001 for
pioglitazonevsrosiglitazone
DPP4,dipeptidylpeptidase
those that are large and continue for long enough to assess extra-skeletal effects, or used doses of vitamin D
generate reliable results by accruing more than 1,000 that were likely inadequate to promote extra-skeletal
primary outcomes [45–47]. Without such trials, some effects [37, 39]. Nevertheless, these data and data from
therapies that are now known to be harmful would have physiological studies have been used to actively promote
been promoted because they were considered to be its use for such indications. An ongoing trial of 20,000
beneficial based on weaker evidence (e.g. suppression of people (ClinicalTrials.gov NCT01169259) is likely to
ventricular premature beats after a myocardial infarction resolve this uncertainty.
[48]) whereas other therapies that are now known to be The strengths of TIDE were its placebo-controlled
beneficial would have been abandoned because they were design, large size, inclusion of a research question
considered to be harmful based on weaker evidence (e.g. regarding vitamin D in addition to the TZD questions,
lowering of systolic blood pressure in the elderly [49] and safety oversight by an independent data monitoring
beta-blockers in heart failure [50]). committee and independent scientific leadership. Its main
As with the TZDs, no conclusion regarding the weakness was its timing. Had it been initiated earlier it is
effects of vitamin D on cancers and mortality can be likely that its results would have pre-empted premature
drawn. Previous randomised trials were not designed to conclusions and claims by various organisations and
44 Diabetologia(2012)55:36–45
individuals regarding the efficacy and safety of rosiglita- tolerance or impaired fasting glucose: a randomised controlled
zone or pioglitazone. Indeed, the results would have
trial.Lancet368:1096–1105
3. DeFronzoRA,TripathyD,SchwenkeDCetal(2011)Pioglitazone
providedclearevidencetoinformmedicalcare.Thehistory
fordiabetespreventioninimpairedglucosetolerance.NEnglJMed
of TIDE therefore highlights the importance of conducting 364:1104–1115
well-designed outcomes trials such as TIDE early in the 4. KahnSE,HaffnerSM,HeiseMAetal(2006)Glycemicdurability
lifecycle of drugs that are likely to be used for the ongoing of rosiglitazone, metformin, orglyburide monotherapy. NEngl J
Med355:2427–2443
treatment of chronic diseases such as diabetes.
5. TanM,JohnsD,GonzalezGGetal(2004)Effectsofpioglitazone
and glimepiride on glycemic control and insulin sensitivity in
Mexican patients with type 2 diabetes mellitus: a multicenter,
randomized,double-blind,parallel-grouptrial.ClinTher26:680–693
Contribution statement ZP and HCG had full access to all of the 6. QayyumR,AdomaityteJ(2006)Ameta-analysisoftheeffectof
data in the study and take responsibility for the integrity of the data thiazolidinediones on blood pressure. J Clin Hypertens
andtheaccuracyofthedataanalysis.HCG,JB,SY,ZP,GD,RD,RH, (Greenwich) 8:19–28
JLP,AR,MCR,LERandBZcontributedtostudyconceptanddesign. 7. SarafidisPA,StafylasPC,GeorgianosPI,SaratzisAN,LasaridisAN
RAcontributedtodataanalysis.ZPandHCGcontributedtodrafting (2010)Effectofthiazolidinedionesonalbuminuriaandproteinuriain
of the manuscript. JB, GD, RD, JH, JLP, AR, MCR, LER, BZ, RA diabetes:ameta-analysis.AmJKidneyDis55:835–847
andSYcontributedtocriticalrevisionofthemanuscriptforimportant 8. Dagenais GR, Gerstein HC, Holman R et al (2008) Effects of
intellectualcontent.Allauthorsapprovedthefinalversion. ramiprilandrosiglitazoneoncardiovascularandrenaloutcomesin
people with impaired glucose tolerance or impaired fasting
glucose: results of the Diabetes REduction Assessment with
Duality of interest H. C. Gerstein, S. Yusuf and Z. Punthakee’s ramipril and rosiglitazone Medication (DREAM) trial. Diabetes
institution received funding to conduct the TIDE trial from Glaxo- Care31:1007–1014
SmithKline,manufacturerofrosiglitazone.Z.Punthakeehasreceived 9. Lachin JM, Viberti G, Zinman B et al (2011) Renal function in
honoraria for advice and speaking from GlaxoSmithKline, type 2 diabetes with rosiglitazone, metformin, and glyburide
Boehringer Ingelheim, Lilly, Merck Frosst, NovoNordisk and sanofi- monotherapy.ClinJAmSocNephrol6:1032–1040
aventis. G. Dagenais has received consulting and lecture fees from 10. Vijay SK, Mishra M, Kumar H, Tripathi K (2009) Effect of
GlaxoSmithKline, Boehringer Ingelheim and sanofi-aventis and grant pioglitazone and rosiglitazone on mediators of endothelial
support from sanofi-aventis. R. Diaz has received consulting fees or dysfunction,markersofangiogenesisandinflammatorycytokines
honoraria and other research support from Bristol-Myers Squibb. R. intype-2diabetes.ActaDiabetol46:27–33
Holman has received research support from Amylin, Bayer, Merck 11. RicheDM,ValderramaR,HenyanNN(2007)Thiazolidinediones
and Novartis, attended advisory boards with Amylin, Lilly, Merck, and risk of repeat target vessel revascularization following
Novartis and Novo Nordisk, and given lectures supported by Bayer, percutaneous coronary intervention: a meta-analysis. Diabetes
Lilly, Merck and Merck Serono. A. Ramachandran has received Care30:384–388
honoraria for advice and speaking from sanofi-aventis, MSD and 12. LonnEM,GersteinHC,SheridanPetal(2009)Effectoframipril
Lilly. M. C. Riddle has received honoraria for consulting and/or and of rosiglitazone on carotid intima-media thickness in people
speakingfromAmylin,Lilly,NovoNordiskandsanofi-aventis,and with impaired glucose tolerance or impaired fasting glucose:
alsoresearch grant support throughhis institutionfrom Amylin, Lilly, STARR(STudyofAtherosclerosiswithRamiprilandRosiglitazone).
GlaxoSmithKline and sanofi-aventis. L. E. Rydén has received JAmCollCardiol53:2028–2035
honoraria for advice and lectures by AstraZeneca, Roche and 13. Mazzone T, Meyer PM, Feinstein SB et al (2006) Effect of
Bristol-MyersSquibb.B.Zinmanhasreceivedhonorariaforconsulting pioglitazone compared with glimepiride on carotid intima-
fromGlaxoSmithKlineandLilly.S.Yusufhasreceivedconsultingfees media thickness in type 2 diabetes: a randomized trial. JAMA
from Boehringer Ingelheim, sanofi-aventis, Novartis, AstraZeneca, 296:2572–2581
Bristol-MyersSquibbandGlaxoSmithKline.H.C.Gersteinhasreceived 14. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC (2004) Effect of
honoraria for consulting and speaking from GlaxoSmithKline, sanofi- rosiglitazoneoncommoncarotidintima-mediathicknessprogression
aventis, Lilly, Novo Nordisk, Bayer, Merck, Johnson and Johnson, in coronary artery disease patients without diabetes mellitus.
Roche,AbbotandAstraZeneca.Theremainingauthorsdeclarethatthey ArteriosclerThrombVascBiol24:930–934
havenodualityofinterestassociatedwiththismanuscript.Fundingand 15. Choi D, Kim SK, Choi SH et al (2004) Preventative effects of
supply of the investigational medicines for this trial was provided by rosiglitazone on restenosis after coronary stent implantation in
GlaxoSmithKline, the manufacturer of rosiglitazone. In collaboration patientswithtype2diabetes.DiabetesCare27:2654–2660
withH.C.Gerstein,S.Yusufandaninternationalscientificcommittee, 16. Nissen SE, Nicholls SJ, Wolski K et al (2008) Comparison of
thesponsorGlaxoSmithKlinehad inputtothedesign ofthetrial.The pioglitazone vs glimepiride on progression of coronary athero-
sponsorreviewedthemanuscriptandprovidedminorcomments. sclerosis in patients with type 2 diabetes: the PERISCOPE
randomizedcontrolledtrial.JAMA299:1561–1573
17. InzucchiSE,MasoudiFA,WangYetal(2005)Insulin-sensitizing
antihyperglycemic drugs and mortality after acute myocardial
References infarction:insightsfromtheNationalHeartCareProject.Diabetes
Care28:1680–1689
18. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM,
1. Phung OJ, Scholle JM, Talwar M, Coleman CI (2010) Effect of Krumholz HM (2005) Thiazolidinediones, metformin, and out-
noninsulin antidiabetic drugs added to metformin therapy on comes in older patients with diabetes and heart failure: an
glycemic control, weight gain, and hypoglycemia in type 2 observationalstudy.Circulation111:583–590
diabetes.JAMA303:1410–1418 19. FryeRL,AugustP,BrooksMMetal(2009)Arandomizedtrialof
2. GersteinHC,YusufS,BoschJetal(2006)Effectofrosiglitazone therapiesfortype2diabetesandcoronaryarterydisease.NEnglJ
on the frequency of diabetes in patients with impaired glucose Med360:2503–2515
Diabetologia(2012)55:36–45 45
20. HomePD,PocockSJ,Beck-NielsenHetal(2009)Rosiglitazone 34. Wang TJ, Pencina MJ, Booth SL et al (2008) Vitamin D
evaluated for cardiovascular outcomes in oral agent combination deficiency and risk of cardiovascular disease. Circulation
therapyfortype2diabetes(RECORD):amulticentre,randomised, 117:503–511
open-labeltrial.Lancet373:2125–2135 35. Autier P, Gandini S (2007) Vitamin Dsupplementation and total
21. DormandyJA,CharbonnelB,EcklandDJetal(2005)Secondary mortality: a meta-analysis of randomized controlled trials. Arch
prevention of macrovascular events in patients with type 2 InternMed167:1730–1737
diabetes in the PROactive Study (PROspective pioglitAzone 36. HsiaJ,HeissG,RenHetal(2007)Calcium/vitaminDsupplemen-
ClinicalTrialInmacroVascularEvents):arandomisedcontrolled tationandcardiovascularevents.Circulation115:846–854
trial.Lancet366:1279–1289 37. Wactawski-Wende J, Kotchen JM, Anderson GL et al (2006)
22. KaulS,BolgerAF,HerringtonD,GiuglianoRP,EckelRH(2010) CalciumplusvitaminDsupplementationandtheriskofcolorectal
Thiazolidinedione drugs and cardiovascular risks: a science cancer.NEnglJMed354:684–696
advisory from the American Heart Association and American 38. ChlebowskiRT,JohnsonKC,KooperbergCetal(2008)Calcium
CollegeofCardiologyFoundation.Circulation121:1868–1877 plus vitamin D supplementation and the risk of breast cancer. J
23. Yki-Jarvinen H (2005) The PROactive Study: some answers, NatlCancerInst100:1581–1591
manyquestions.Lancet366:1241–1242 39. LappeJM,Travers-GustafsonD,DaviesKM,ReckerRR,Heaney
24. FreemantleN(2005)Howwelldoestheevidenceonpioglitazone RP (2007) Vitamin D and calcium supplementation reduces
back up researchers' claims for a reduction in macrovascular cancer risk: results of a randomized trial. Am J Clin Nutr
events?BMJ331:836–838 85:1586–1591
25. Lago RM, Singh PP, Nesto RW (2007) Congestive heart failure 40. Harris G (2010) Research ties diabetes drug to heart woes. New
and cardiovascular death in patients with prediabetes and type 2 YorkTimes,19February2010
diabetes given thiazolidinediones: a meta-analysis of randomised 41. Baucus M, Grassley C (2010) Staff report on GlaxoSmithKline
clinicaltrials.Lancet370:1129–1136 and the diabetes drug Avandia 111-41. US Government Printing
26. Mannucci E, Monami M, Di BM et al (2010) Cardiac safety Office,Washington
profile of rosiglitazone: a comprehensive meta-analysis of 42. FoodandDrugAdministrationFDADrugSafetyCommunication:
randomizedclinicaltrials.IntJCardiol143:135–140 ongoing review of Avandia (rosiglitazone) and cardiovascular
27. Nagajothi N, Adigopula S, Balamuthusamy S et al (2008) safety (2010). Available from www.fda.gov/Drugs/DrugSafety/
Pioglitazoneandtheriskofmyocardialinfarctionandothermajor PostmarketDrugSafetyInformationforPatientsandProviders/
adversecardiacevents:ameta-analysisofrandomized,controlled ucm201418.htm.Accessed9May2011
trials.AmJTher15:506–511 43. MundyA,CorbettDoorenJ(2010)FDAweighshaltingavandia
28. RichterB,Bandeira-EchtlerE,BergerhoffK,ClarC,EbrahimSH safetystudy.WallStreetJournal19April2010
(2006) Pioglitazone for type 2 diabetes mellitus Cochrane 44. WeykampC,JohnWG,MoscaAetal(2008)TheIFCCreference
Database Syst Rev 4:CD006060. doi:10.1002/14651858. measurement system for HbA1c: a 6-year progress report. Clin
CD006060.pub2 Chem54:240–248
29. RichterB,Bandeira-EchtlerE,BergerhoffK,ClarC,EbrahimSH 45. Gerstein HC, Yusuf S (2010) Clinical outcomes trials and the
(2007) Rosiglitazone for type 2 diabetes mellitus Cochrane cardiovascular effects of thiazolidinediones: implications for the
Database Syst Rev 3:CD006063. doi:10.1002/14651858. evaluationofantidiabeticdrugs.AmHeartJ160:1–2
CD006063.pub2 46. BaigentC,PetoR,GrayR,ParishS,CollinsR(2010)Large-scale
30. Food and Drug Administration briefing document: 13–14 July randomized evidence: trials and meta-analyses of trials. In:
2010 Meeting of the Endocrinologic and Metabolic Drugs Warrell DA, Cox TM, Firth JD (eds) Oxford textbook of
Advisory Committee (2011). Available from www.fda.gov/ medicine,5thedn.OxfordUniversityPress,Oxford,pp31–45
AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ 47. Yusuf S, CollinsR,Peto R(1984) Whydoweneed somelarge,
EndocrinologicandMetabolicDrugsAdvisoryCommittee/ simplerandomizedtrials?StatMed3:409–422
ucm191113.htm.Accessed25April2011 48. Echt DS, Liebson PR, Mitchell LB et al (1991) Mortality and
31. ScraggR,SowersM,BellC(2004)Serum25-hydroxyvitaminD, morbidityinpatientsreceivingencainide,flecainide,orplacebo—
diabetes,andethnicityintheThirdNationalHealthandNutrition The Cardiac Arrhythmia Suppression Trial. N Engl J Med
ExaminationSurvey.DiabetesCare27:2813–2818 324:781–788
32. Holick MF (2010) Vitamin D: extraskeletal health. Endocrinol 49. Anonymous (1991) Prevention of stroke by antihypertensive drug
MetabClinNorthAm39:381–400 treatmentinolderpersonswithisolatedsystolichypertensionFinal
33. Cigolini M, Iagulli MP, Miconi V, Galiotto M, Lombardi S, resultsoftheSystolicHypertensionintheElderlyProgram(SHEP)
Targher G (2006) Serum 25-hydroxyvitamin D3 concentrations SHEPCooperativeResearchGroup.JAMA265:3255–3264
and prevalence of cardiovascular disease among type 2 diabetic 50. Foody JM, Farrell MH, Krumholz HM (2002) Beta-blocker
patients.DiabetesCare29:722–724 therapyinheartfailure:scientificreview.JAMA287:883–889
